These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12197225)

  • 41. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer.
    Escobar PF; Markman M; Zanotti K; Webster K; Belinson J
    J Cancer Res Clin Oncol; 2003 Nov; 129(11):651-4. PubMed ID: 14505047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
    Samson MK; Wasser LP; Borden EC; Wanebo HJ; Creech RH; Phillips M; Baker LH
    J Clin Oncol; 1987 Jan; 5(1):86-91. PubMed ID: 3543239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vindesine in the treatment of malignant mesothelioma: a phase II study.
    Kelsen D; Gralla R; Cheng E; Martini N
    Cancer Treat Rep; 1983 Sep; 67(9):821-2. PubMed ID: 6883358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
    Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
    Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
    Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
    Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
    Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin.
    Harvey VJ; Slevin ML; Ponder BA; Blackshaw AJ; Wrigley PF
    Cancer; 1984 Sep; 54(6):961-4. PubMed ID: 6467141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study [corrected from prospective].
    Tsavaris N; Primikirios N; Mylonakis N; Varouchakis G; Dosios T; Pavlidis N; Skarlos D; Tasopoulos T; Dritsas J; Kosmidis P
    Anticancer Res; 1997; 17(5B):3799-802. PubMed ID: 9427783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
    Safra T; Muggia F; Jeffers S; Tsao-Wei DD; Groshen S; Lyass O; Henderson R; Berry G; Gabizon A
    Ann Oncol; 2000 Aug; 11(8):1029-33. PubMed ID: 11038041
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
    Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
    Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
    Calabrò L; Morra A; Giannarelli D; Amato G; D'Incecco A; Covre A; Lewis A; Rebelatto MC; Danielli R; Altomonte M; Di Giacomo AM; Maio M
    Lancet Respir Med; 2018 Jun; 6(6):451-460. PubMed ID: 29773326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
    Sørensen PG; Bach F; Bork E; Hansen HH
    Cancer Treat Rep; 1985 Dec; 69(12):1431-2. PubMed ID: 3907825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
    Kindler HL; Herndon JE; Zhang C; Green MR;
    Lung Cancer; 2005 Jun; 48(3):423-8. PubMed ID: 15893012
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma.
    Halford S; Yip D; Karapetis CS; Strickland AH; Steger A; Khawaja HT; Harper PG
    Ann Oncol; 2001 Oct; 12(10):1399-402. PubMed ID: 11762810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II study of liposomal doxorubicin in advanced gynecologic cancers.
    Israel VP; Garcia AA; Roman L; Muderspach L; Burnett A; Jeffers S; Muggia FM
    Gynecol Oncol; 2000 Aug; 78(2):143-7. PubMed ID: 10926793
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety aspects of pegylated liposomal doxorubicin in patients with cancer.
    Alberts DS; Garcia DJ
    Drugs; 1997; 54 Suppl 4():30-5. PubMed ID: 9361959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.